Skip to content Skip to footer
Sanofi’s latest Dupixent win and Eupraxia Pharmaceuticals’ quiet grind in eosinophilic esophagitis (“EoE”) still tell a coherent, investor‑friendly story: the type 2 inflammation boom is alive, and there is room on the highway for both mega‑cap platforms and focused innovators. For investors,…
Butterfly Network’s (BFLY) Midjourney cameo now sits inside a bigger, more nuanced script: AI‑driven imaging that can delight investors, unnerve ethicists, and occasionally confuse radiologists—all while telehealth platforms like Amwell (AMWL) quietly wire the whole thing into everyday care. The result is…
Your Guide To Staying Informed In The Markets

Subscribe For Free Email Updates Access To Exclusive Research

Vista Partners — © 2026 — Vista Partners LLC (“Vista”) is a Registered Investment Advisor in the State of California. Vista is not licensed as a broker, broker-dealer, market maker, investment banker, or underwriter in any jurisdiction. By viewing this website and all of its pages, you agree to our terms. Read the full disclaimer here